98%
921
2 minutes
20
Purpose: Maternal remifentanil infusion is used for minimally invasive fetal surgery or ex-utero intrapartum treatment. The fetal-to-maternal (F/M) ratio of remifentanil concentration at various dosing regimens is useful to manage remifentanil effects. The aim of this study was to investigate the F/M ratio of remifentanil at various concentrations.
Methods: Five pregnant ewes received continuous remifentanil infusion under propofol anesthesia. The remifentanil infusion rate was increased by 0.4 µg/kg/min every 15 min. The response to tail clamping in fetuses was assessed immediately before the change of infusion rate. Arterial remifentanil concentrations in the mother and fetus were determined at each tail clamp. After observing a loss of response to tail clamping, remifentanil infusion was terminated and the concentrations were assessed.
Results: The median remifentanil maximum infusion rate and maternal concentration were 3.0 µg/kg/min (range 2.4-3.6) and 21.6 (range 18.0-29.9) ng/mL, respectively. During continuous infusion, the F/M ratio was 0.15 (0.07-0.17), and the slope of the linear regression for the F/M ratio versus infusion rate in each individual was -0.001 ± 0.012/μg kg min (P = 0.876 vs hypothetical value of 0). The F/M ratio at the first sampling point in the elimination phase [0.33 (0.07-0.65)] was higher (P = 0.033) than at the last sampling point during continuous infusion [0.15 (0.06-0.17)].
Conclusion: The F/M ratio was constant at a steady state regardless of the remifentanil concentration up to 29.9 ng/mL, and increased in the elimination phase in pregnant ewes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00540-017-2332-4 | DOI Listing |
Circulation
September 2025
Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA (J.C., C.G., C.N., S.M., I.G., F.M., A.M., C.P., L.R., I.L., N.I., R.M., G.D.L.).
Background: Post-exercise oxygen uptake recovery (VORec) is slow in advanced heart failure. We sought to establish easily derived VORec measures and evaluate their cardiospecificity and prognostic relevance in patients with dyspnea on exertion. We further sought to determine VORec modifiability proportional to changes in cardiac function with disease-specific treatment of obstructive hypertrophic cardiomyopathy.
View Article and Find Full Text PDFJAMA Netw Open
August 2025
Department of Cardiology, Barbra Streisand Women's Heart Center, Cedars-Sinai Smidt Heart Institute, Los Angeles, California.
Importance: Cardiovascular (CV) disease is the leading cause of death globally for both men and women, yet women remain historically underrepresented in CV clinical trials, despite facing a disproportionately high burden of morbidity and mortality in many forms of CV disease.
Objective: To determine the representation of women across a broad range of CV trials.
Evidence Review: The participation of women in CV trials registered on ClinicalTrials.
Nat Med
August 2025
Eli Lilly and Company, Indianapolis, IN, USA.
Relaxin is a peptide hormone that may decrease circulatory congestion and improve kidney function. In this study, we conducted a double-blind, international, multicenter trial to test whether volenrelaxin, a long-acting form of human relaxin, can improve left atrial (LA) function, reduce congestion and improve kidney function in patients with heart failure and preserved ejection fraction (HFpEF). We randomly assigned patients with New York Heart Association (NYHA) class II-IV HFpEF and recent heart failure (HF) decompensation to 25-mg, 50-mg or 100-mg volenrelaxin or placebo administered subcutaneously once weekly.
View Article and Find Full Text PDFNPJ Microgravity
August 2025
Department of Applied Physiology and Kinesiology, University of Florida, Gainesville, FL, USA.
More people are traveling to space for longer durations than ever before. Many long-duration flyers exhibit signs of Spaceflight Associated Neuro-ocular Syndrome (SANS). A greater understanding of the mechanisms and predictors of SANS may lead to new, more individually tailored countermeasures.
View Article and Find Full Text PDFCNS Drugs
August 2025
Department of Physiology and Pharmacology, Federal University of Pernambuco, Recife, PE, Brazil.
Background: Agitation is a common and distressing neuropsychiatric symptom in Alzheimer's disease (AD), affecting up to half of patients and contributing to faster cognitive decline and caregiver burden. Brexpiprazole, a serotonin-dopamine modulator, has been evaluated for this indication, but uncertainties remain regarding its efficacy, safety, and appropriate use in older adults.
Objective: We aimed to assess the efficacy and safety of brexpiprazole for the treatment of agitation in older adults with AD through a systematic review and meta-analysis of randomized controlled trials (RCTs).